Perrigo Co PLC (PRGO): R&D Expense
$95.40M
Year ended 2025-12-31
$95.10M
Trailing 12 months to 2026-06-27
-8.1%
3-year compound annual growth
-4.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $95.40M | -15.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $112.20M | -8.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $122.50M | -0.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $123.10M | +0.9% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $122.00M | +0.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $121.70M | +2.1% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $119.20M | n/c | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $218.60M | +30.4% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $167.70M | -8.9% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $184.00M | n/a | 2019-02-27, From 2016-01-01 |
| No annual figure between 2015-06-27 and 2016-12-31. | |||
| 2015-06-27 | $187.80M | +23.1% | 2018-03-01, From 2014-06-29 |
| 2014-06-28 | $152.50M | +32.4% | 2017-05-22, From 2013-06-30 |
| 2013-06-29 | $115.20M | +8.9% | 2015-08-13, From 2012-07-01 |
| 2012-06-30 | $105.80M | n/a | 2014-08-14, From 2011-06-26 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Perrigo Co PLC (PRGO) | 2025-12-31 | $95.40M | -15.0% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $782.74M | -11.5% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $368.00M | +7.0% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.32B | +17.2% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $2.15B | +9.9% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $921.93M | +23.4% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $550.00M | +14.3% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $186.18M | -2.4% |
| Organon & Co. (OGN) | 2025-12-31 | $366.00M | -22.0% |
Compare PRGO, JAZZ, ELAN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗